EODData

MEMBERSHIP REGISTER LOG IN

FRA, 04X: PERSONALIS INC. DL-001

06 Nov 2025
LAST:

6.480

CHANGE:
 0.34		OPEN:
6.480		HIGH:
6.480		ASK:
0.000		VOLUME:
0
CHG(%):
5.54		PREV:
6.140		LOW:
6.480		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
06 Nov 256.4806.4806.4806.4800
05 Nov 256.1406.1406.1406.1400
04 Nov 257.3557.3557.3557.3551.5K
31 Oct 258.2258.2258.2258.2250
30 Oct 258.1408.1408.1408.1400
29 Oct 258.3508.3508.3508.3500
28 Oct 258.2358.2358.2358.2350
27 Oct 258.3708.3708.3708.3700
24 Oct 258.0008.0008.0008.0000
23 Oct 257.5307.5307.5307.5300

COMPANY PROFILE

Name:PERSONALIS INC. DL-001
About:Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company has strategic collaboration with Tempus AI, Inc. to bring ultra-sensitive cancer recurrence testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.
Address:6600 Dumbarton Circle, Fremont, CA, United States, 94555
Website:https://www.personalis.com
ISIN:US71535D1063
LEI:549300EZ2NYFK7H0US48

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:7.2712.2%
MA10:7.6818.6%
MA20:7.6017.2%
MA50:5.8311.2%
MA100:5.4419.2%
MA200:4.7237.2%
STO9:15.25 
STO14:14.47 
RSI14:43.82
WPR14:-85.53 
MTM14:-1.66
ROC14:-0.20 
ATR:0.50 
Week High:8.2326.9%
Week Low:6.145.5%
Month High:8.4931.0%
Month Low:6.1437.2%
Year High:8.4931.0%
Year Low:2.57151.7%